We are live on ! Find out more
VCYT icon

Veracyte

250 hedge funds and large institutions have $2.14B invested in Veracyte in 2023 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 80 increasing their positions, 105 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

46% more call options, than puts

Call options by funds: $2.83M | Put options by funds: $1.95M

25% more capital invested

Capital invested by funds: $1.72B → $2.14B (+$425M)

6% more funds holding

Funds holding: 236250 (+14)

1.23% more ownership

Funds ownership: 105.34%106.57% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

24% less repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 105

Holders
250
Holders Change
+14
Holders Change %
+5.93%
% of All Funds
3.64%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
35
Increased
80
Reduced
105
Closed
20
Calls
$2.83M
Puts
$1.95M
Net Calls
+$887K
Net Calls Change
-$1.17M

VCYT Hedge Fund Activity: Q4 2023 in Review

250 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q4 2023, worth a combined $2.14B — up 25% from $1.72B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new VCYT positions and 20 closed out — a net gain of 15 holders — while 80 added to existing stakes and 105 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $21.6M. The largest seller was Point72 Asset Management, cutting an estimated $9.59M.

  • 250 institutional investors held Veracyte (VCYT) as of Q4 2023, up from 236 in Q3 2023.
  • Funds reported $2.14B of Veracyte stock for Q4 2023, up 25% quarter-over-quarter.
  • 35 funds opened new Veracyte positions in Q4 2023 and 20 closed out, a net change of +15 holders.
  • The largest Veracyte buyer in Q4 2023 was Morgan Stanley, an estimated $21.6M added.
  • The largest Veracyte seller in Q4 2023 was Point72 Asset Management, an estimated $9.59M sold.

Based on aggregated 13F filings for Q4 2023.